Posted 11 November 2019
In March 2019, Natasha Bolognesi wrote an article for GroundUp, making the point: “But practitioners of so-called mild hyperbaric oxygen therapy (mHBOT) are fraudulently cashing in on the science that supports medically-approved HBOT”. She also stated that “The South African company O2xygenate claims mHBOT can be used for a string of indications including cancer, stroke, Parkinson’s disease, Alzheimer’s disease, autism, arthritis, multiple sclerosis and cerebral palsy amongst others – none of which is approved for treatment with HBOT or mHBOT”.
Now Health Canada is advising Canadians that this treatment needs to be avoided, making the point that “the operators of some private clinics claim it can also be used to treat such conditions as multiple sclerosis, cerebral palsy, cancer, AIDS, stroke and migraine headaches. There is no scientific proof to support these claims”.
Warning issued about unauthorized soft-shelled hyperbaric chambers.
Health Canada is advising Canadians that:
- Soft-shelled hyperbaric chambers that are promoted online or offered as a service to treat a medical conditions such as autism, cerebral palsy and migraines are unauthorized medical devices and may pose serious health risks, including death.
- Manufacturers have not demonstrated that the soft-shelled models are effective for treating any medical condition.
Reference: Unauthorized soft-shelled hyperbaric chambers may pose serious health risks. Health Canada safety alert, Oct 25, 2019
- The potential risks of the soft-shelled chambers include:
- fire or explosion as a result of static discharge within an elevated oxygen environment with a significantly increased risk when used in combination with a concentrated oxygen device
- disease spread through cross-contamination between users
- damage to the ears, eyes, sinuses, lungs and teeth
- changes to blood sugar levels.
Health Canada has updated its hyperbaric oxygen information page for consumers